Prospects for prevention of HPV-driven oropharynx cancer.

  title={Prospects for prevention of HPV-driven oropharynx cancer.},
  author={Aim{\'e}e R. Kreimer},
  journal={Oral oncology},
  volume={50 6},
  • A. Kreimer
  • Published 1 June 2014
  • Medicine, Biology
  • Oral oncology

Figures and Tables from this paper

Immunoprevention of Human Papillomavirus–Associated Malignancies

Recent progress and opportunities to better prevent HPV-associated cancers are reviewed, including broadening immune protection to cover all hrHPV types, reducing the cost of HPV vaccines especially for developing countries that have the highest rates of cervical cancer, and immune-based treatment of established HPV infections.

Recent Progress in Therapeutic Treatments and Screening Strategies for the Prevention and Treatment of HPV-Associated Head and Neck Cancer

The future for developing novel and effective therapeutic agents for HPV-associated head and neck tumors is promising; continued progress is critical in order to meet the challenges posed by the growing epidemic.

Human papillomavirus-related oropharyngeal cancer in the HIV-infected population.

Although not demonstrated in randomized controlled trials, HPV vaccination may prevent oral HPV infection as well and the focus of organized HPV cancer prevention programs should include prophylactic HPV vaccination to reduce the burden of high-risk HPV and low- risk HPV types who have not yet been exposed.

Disparities in HPV vaccination rates and HPV prevalence in the United States: a review of the literature

  • J. Hirth
  • Medicine, Biology
    Human vaccines & immunotherapeutics
  • 2019
U uptake of the HPV vaccine remains modest, despite evidence that vaccine-type HPV prevalence is decreasing as a result of HPV vaccination, and geographic disparities in vaccination uptake across different US regions and by race/ethnicity may contribute to continuing disparities in HPV-related cancers.

Targeted Therapy in Oropharyngeal Squamous Cell Carcinoma: The Implications of HPV for Therapy

A summary of the current understanding of HPV in head and neck cancer and the important advances that have shown HPV to be an etiological agent are discussed and the treatment options for patients with HPV-positive disease are likely to change in the future.

Long-term Persistence of Oral Human Papillomavirus Type 16: The HPV Infection in Men (HIM) Study

Prevalent oral HPV16 infections in men persisted longer than newly acquired infections, and persistence appeared to increase with age, which may explain the high prevalence of oral HPV observed at older ages.

Human papillomavirus antibodies and future risk of anogenital cancer: a nested case-control study in the European prospective investigation into cancer and nutrition study.

  • A. KreimerP. Brennan M. Johansson
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2015
HPV16 E6 seropositivity is relatively common before diagnosis of anal cancer but rare for other HPV-related anogenital cancers.



Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males.

Quadrivalent HPV vaccine prevents infection with HPV-6, 11, 16, and 18 and the development of related external genital lesions in males 16 to 26 years of age.

Reduced Prevalence of Oral Human Papillomavirus (HPV) 4 Years after Bivalent HPV Vaccination in a Randomized Clinical Trial in Costa Rica

HPV prevalence four years after vaccination with the ASO4-adjuvanted HPV 16/18 vaccine was much lower among women in the vaccine arm compared to the control arm, suggesting that the vaccine affords strong protection against oral HPV16/18 infection, with potentially important implications for prevention of increasingly common HPV-associated oropharyngeal cancer.

Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine

The long-term efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine (Cervarix®) up to 8.4 y after the first vaccine dose was reported, and the safety profile was clinically acceptable for both vaccine and control groups.

Human Papillomavirus mRNA and p16 Detection as Biomarkers for the Improved Diagnosis of Cervical Neoplasia

There is promising data indicating that HPV mRNA and p16 might play an important role in future cervical cancer screening scenarios, still, large randomized studies are necessary to confirm the preliminary data.

Associations between Oral HPV16 Infection and Cytopathology: Evaluation of an Oropharyngeal “Pap-Test Equivalent” in High-Risk Populations

Tonsillar HPV16 infection was not associated with atypical squamous cells of unknown significance (ASCUS), the only cytologic abnormality identified, and HPV16 was associated with OSCCs among individuals with accessible oropharyngeal lesions but not with cytologic evidence of dysplasia among high-risk individuals without such lesions.

Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial.

In women positive for HPV DNA, HPV-16/18 vaccination does not accelerate clearance of the virus and should not be used to treat prevalent infections.

HPV vaccine against anal HPV infection and anal intraepithelial neoplasia.

Use of the qHPV vaccine reduced the rates of anal intraepithelial neoplasia, including of grade 2 or 3, among men who have sex with men and had a favorable safety profile and may help to reduce the risk of anal cancer.

Vaccine-Type Human Papillomavirus and Evidence of Herd Protection After Vaccine Introduction

There was a substantial decrease in vaccine-type HPV prevalence and evidence of herd protection in this community four years after licensing of the quadrivalent HPV vaccine.